Xiaohua Hu

机构：Guangxi Medical University, Second Military Medical University, Zunyi Medical University, Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, Beijing Jishuitan Hospital, Institute of Plant Protection, Shanghai Changzheng Hospital, JiangSu Armed Police General Hospital, CITIC Group (China), First Affiliated Hospital of GuangXi Medical University, Chinese Academy of Agricultural Sciences, Shanghai Zhabei District Shibei Hospital, Data Management (Italy) · ORCID：0000-0002-2161-1324

发表论文 236 篇 · 总被引 3469 次 · h-index 32

代表论文

• Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial (2024 · Nature Medicine · 被引 177)
• Programming of macrophage polarization in different stages for accelerating wound healing (2024 · Chemical Engineering Journal · 被引 58)
• Antioxidative bioactive glass reinforced injectable hydrogel with reactive oxygen species scavenging capacity for diabetic wounds treatment (2024 · Chemical Engineering Journal · 被引 54)
• Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial (2024 · Signal Transduction and Targeted Therapy · 被引 36)
• Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. (2024 · Journal of Clinical Oncology · 被引 35)
• Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation (2025 · Signal Transduction and Targeted Therapy · 被引 20)